A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report symptoms, view educational content in video form about IO and irAEs and communicate with site study team.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Subject with a confirmed cancer diagnosis and prescribed checkpoint inhibitor therapy.
Confirmed cancer diagnosis
Prescribed treatment with immune-checkpoint inhibitor
Age ≥ 18 years
Ability to understand and the willingness to sign a written informed consent document.
Uncomfortable with or unwilling to use digital or mobile technology
Lack of a smart phone with compatible operating systems: iOS version 10 and above, or Android 6.0 Marshmallow
Presence of any medical, psychological or social condition that, in the opinion of the investigator, would preclude participation in this study.